Market Overview

UPDATE: Allergan Upgraded by Citigroup on Strong Fundamentals

Related AGN
Don't Worry Spec. Pharma Investors, Drug Pricing Legislation Probably Won't Affect You
US Stock Futures Gain Ahead Of Economic Data
Acorda Soars, Settles Ampyra Patent Dispute with Allergan (Zacks)

Tuesday morning rating updates include an upgrade from Citigroup analyst Liav Abraham, boosting Allergen (NYSE: AGN) from Neutral to Buy, with a price rating of $130 from $95.

Citigroup is sold on Allergan's long-term growth with strong balance sheet and cash flow to back up their rating change. The report notes, "Following the recent removal of the Restasis and Lumigan overhangs, the fundamental risk-reward profile of AGN has shifted, in our view, with the stock offering the most attractive organic growth profile amongst the peer group, along with significant balance sheet optionality."

AGN is currently trading up around the $114 mark after closing Monday at $112.26.

Latest Ratings for AGN

Sep 2015NomuraInitiates Coverage onBuy
Sep 2015Raymond JamesMaintainsOutperform
Aug 2015JP MorganReinstatesOverweight

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Citigroup Liav AbrahamUpgrades Price Target Analyst Ratings


Related Articles (AGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters